OrthoPediatrics Corp. Reports Second Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance

Core Insights - OrthoPediatrics Corp. reported a record revenue of $61.1 million for Q2 2025, marking a 16% increase year-over-year, with adjusted EBITDA rising by 58% to $4.1 million [1][4][8] Financial Performance - Total revenue for Q2 2025 was $61.1 million, up from $52.8 million in Q2 2024, driven by strong growth in Scoliosis, Trauma, and OPSB products [4][8] - U.S. revenue reached $48.1 million, a 17% increase from $41.2 million in the same quarter last year, accounting for 79% of total revenue [4][8] - International revenue was $12.9 million, a 12% increase from $11.6 million year-over-year [4][8] - Trauma and Deformity revenue grew by 10% to $41.7 million, while Scoliosis revenue surged by 35% to $18.5 million [5][8] - Gross profit for Q2 2025 was $44.0 million, an 8% increase from $40.8 million in Q2 2024, with a gross profit margin of 72% [6][8] Operating Expenses - Total operating expenses increased by 18% to $54.7 million, primarily due to restructuring charges and increased personnel costs [7][8] - Sales and marketing expenses rose by 15% to $19.1 million, driven by higher sales commissions [9][8] - General and administrative expenses increased by 11% to $30.4 million, reflecting higher non-cash stock compensation and additional personnel [10][8] Net Loss and Cash Flow - The net loss for Q2 2025 was $7.1 million, compared to a loss of $6.0 million in Q2 2024, with a GAAP diluted loss per share of ($0.30) [12][8] - Non-GAAP diluted loss per share improved to ($0.11) from ($0.23) year-over-year [12][8] - Cash, cash equivalents, and short-term investments totaled $72.2 million as of June 30, 2025, up from $70.8 million at the end of 2024 [13][8] Business Expansion - The company expanded its OrthoPediatrics Specialty Bracing Division (OPSB) with new clinics and entered two new territories, including its first international operation in Ireland [8] - Full-year 2025 revenue guidance was raised to a range of $237.0 million to $242.0 million, indicating a growth of 16% to 18% compared to the previous year [14][8]